We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Stock Gains Following FDA Approval of the Tendyne System
Read MoreHide Full Article
Abbott Laboratories (ABT - Free Report) has recently received Food and Drug Administration (“FDA”) approval for its Tendyne transcatheter mitral valve replacement (“TMVR”) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (“MAC”).
The Tendyne system expands the company’s comprehensive Structural Heart portfolio.
ABT Stock’s Likely Trend Following the News
After the announcement, Abbott shares edged up 1.3%, finishing at $132.94 yesterday.
The company’s Structural Heart arm benefits from a unique range of product portfolio, which includes MitraClip, a mitral valve transcatheter edge-to-edge repair system, and TriClip, a tricuspid valve transcatheter edge-to-edge repair system. The portfolio also contains transcatheter aortic heart valves — Portico and Navitor. Hence, we expect the market sentiment toward ABT stock to remain positive surrounding the latest development.
Abbott holds a market capitalization of $231.29 billion. The company’s earnings yield of 3.9% surpasses the industry’s 0.6%. ABT delivered an average earnings beat of 1.6% in the trailing four quarters.
Importance of the Tendyne System
MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery.
More on Abbott’s Tendyne System
The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement.
Image Source: Zacks Investment Research
Industry Prospects Favor Abbott
Per Medi-Tech Insights’ report, the TMVR market is projected to witness a compound annual growth rate of 20% from 2025 to 2030. Key factors driving growth are increased prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population.
More Updates From Abbott
Earlier this month, Abbott unveiled results from its REFLECT real-world studies, conducted using data from the comprehensive Swedish National Diabetes Register. The findings revealed that the company’s FreeStyle Libre continuous glucose monitoring (CGM) technology helps significantly reduce the risk of hospitalization for heart complications in people with diabetes.
ABT Stock Price Performance
Over the past year, Abbott’s shares have risen 32%, surpassing the industry’s 10.3% growth.
Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 30.6%. Its shares have rallied 26.3% compared with the industry’s 10% growth in the past year.
AngioDynamics, carrying a Zacks Rank #1 at present, has an estimated earnings growth rate of 23.7% for 2025. ANGO’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 70.85%. ANGO’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.
STERIS, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 10.8% for 2025. STE’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.61%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott Stock Gains Following FDA Approval of the Tendyne System
Abbott Laboratories (ABT - Free Report) has recently received Food and Drug Administration (“FDA”) approval for its Tendyne transcatheter mitral valve replacement (“TMVR”) system. The Tendyne system replaces mitral valves that are not functioning properly due to severe mitral annular calcification (“MAC”).
The Tendyne system expands the company’s comprehensive Structural Heart portfolio.
ABT Stock’s Likely Trend Following the News
After the announcement, Abbott shares edged up 1.3%, finishing at $132.94 yesterday.
The company’s Structural Heart arm benefits from a unique range of product portfolio, which includes MitraClip, a mitral valve transcatheter edge-to-edge repair system, and TriClip, a tricuspid valve transcatheter edge-to-edge repair system. The portfolio also contains transcatheter aortic heart valves — Portico and Navitor. Hence, we expect the market sentiment toward ABT stock to remain positive surrounding the latest development.
Abbott holds a market capitalization of $231.29 billion. The company’s earnings yield of 3.9% surpasses the industry’s 0.6%. ABT delivered an average earnings beat of 1.6% in the trailing four quarters.
Importance of the Tendyne System
MAC stiffens the structure of the mitral valve and can lead to mitral regurgitation or stenosis that disrupts the heart's ability to pump blood effectively. The complex nature of this mitral valve disease and patients' specific needs and health conditions can pose challenges for surgical correction. The Tendyne system offers an alternative, minimally invasive way to replace the valve of patients with severe MAC who are at high risk for open-heart surgery.
More on Abbott’s Tendyne System
The innovative and unique design of the Tendyne system and the valve's availability in multiple sizes allow it to adapt to a range of patient anatomies. The self-expanding valve is delivered through a small incision in the chest and then advanced into the heart to replace the mitral valve. The valve is fully repositionable and retrievable during implantation, allowing for the best possible outcome for people requiring a valve replacement.
Image Source: Zacks Investment Research
Industry Prospects Favor Abbott
Per Medi-Tech Insights’ report, the TMVR market is projected to witness a compound annual growth rate of 20% from 2025 to 2030. Key factors driving growth are increased prevalence of mitral valve diseases, growing preferences for minimally invasive procedures and expanding geriatric population.
More Updates From Abbott
Earlier this month, Abbott unveiled results from its REFLECT real-world studies, conducted using data from the comprehensive Swedish National Diabetes Register. The findings revealed that the company’s FreeStyle Libre continuous glucose monitoring (CGM) technology helps significantly reduce the risk of hospitalization for heart complications in people with diabetes.
ABT Stock Price Performance
Over the past year, Abbott’s shares have risen 32%, surpassing the industry’s 10.3% growth.
ABT’s Zacks Rank and Key Picks
Abbott currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , AngioDynamics (ANGO - Free Report) and STERIS (STE - Free Report) .
PAHC carries a Zacks Rank #1 (Strong Buy) at present. It has an estimated long-term earnings growth rate of 26.2% compared with the industry’s 15.9%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Its earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 30.6%. Its shares have rallied 26.3% compared with the industry’s 10% growth in the past year.
AngioDynamics, carrying a Zacks Rank #1 at present, has an estimated earnings growth rate of 23.7% for 2025. ANGO’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 70.85%. ANGO’s shares have risen 49.2% in the past year compared with the industry’s 5.5% growth.
STERIS, carrying a Zacks Rank #2 (Buy) at present, has an estimated growth rate of 10.8% for 2025. STE’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 0.61%. Its shares have risen 34.1% compared with the industry’s 7.7% growth in the past year.